Verition Fund Management LLC Makes New Investment in Silence Therapeutics plc (NASDAQ:SLN)

Verition Fund Management LLC purchased a new stake in Silence Therapeutics plc (NASDAQ:SLN) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 11,390 shares of the company’s stock, valued at approximately $207,000.

A number of other institutional investors have also modified their holdings of SLN. Values First Advisors Inc. acquired a new stake in Silence Therapeutics in the third quarter worth $56,000. Quarry LP acquired a new stake in shares of Silence Therapeutics in the 2nd quarter worth about $114,000. Custom Index Systems LLC bought a new stake in Silence Therapeutics in the 2nd quarter valued at about $282,000. The Manufacturers Life Insurance Company acquired a new position in Silence Therapeutics during the 3rd quarter valued at about $318,000. Finally, Legato Capital Management LLC bought a new position in Silence Therapeutics in the 2nd quarter worth about $376,000. Institutional investors own 98.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Monday, December 9th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 price target for the company. Morgan Stanley restated an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Finally, Chardan Capital reiterated a “buy” rating and issued a $55.00 target price on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Stock Down 2.3 %

Shares of SLN stock opened at $6.45 on Monday. The stock has a 50-day simple moving average of $13.69 and a 200 day simple moving average of $17.07. The stock has a market capitalization of $193.05 million, a P/E ratio of -4.11 and a beta of 1.05. Silence Therapeutics plc has a fifty-two week low of $5.81 and a fifty-two week high of $27.72.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.